Ozempic lawsuit claims allege that semaglutide and other GLP-1 drugs caused gastroparesis, ileus or intestinal obstruction without adequate warnings. Federal cases are consolidated in MDL 3094 before Judge Karen S. Marston in the Eastern District of Pennsylvania, which listed 4,082 pending actions on November 2, 2026; a separate MDL 3163 for NAION vision loss listed 247. No global settlement has been reported.
Updates on Ozempic Lawsuit
This article supports TortAdvisor's Ozempic Lawsuit Research. For an educational claim-value review, use the Ozempic Settlement Calculator. You can also browse Active Lawsuits and the Ozempic Lawsuit Research. Ozempic lawsuit 2026: Patients who used Ozempic or other GLP-1-related medications and later experienced serious gastrointestinal injuries or certain vision injuries are pursuing product-liability claims alleging inadequate [...]
Key facts (as of November 2026)
- Nov. 2, 2026: 4,082 actions pending in MDL 3094 and 247 in MDL 3163 (JPML).
- Sept. 14–18, 2026: Rule 702 evidentiary hearing on Cross-Cutting Issues 2 and 3 in MDL 3094.
- Dec. 15, 2025: The JPML created MDL 3163 for NAION claims (21 actions in three districts), also before Judge Marston.
- Aug. 15, 2025: A Rule 702 opinion on the first cross-cutting issue cited the medical consensus that objective testing is needed to diagnose gastroparesis.
- June 6, 2025: The European Medicines Agency's safety committee concluded NAION is a very rare side effect of semaglutide (up to 1 in 10,000 users).
What the Ozempic lawsuits claim
Plaintiffs allege that Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Trulicity) did not adequately warn about severe gastrointestinal injuries. The JPML's 2024 order describes claims of gastroparesis, ileus, intestinal obstruction or pseudo-obstruction and other GI injury. Ozempic's current label, revised in October 2025, warns that the drug has been associated with gastrointestinal adverse reactions, sometimes severe, lists ileus and intestinal obstruction among postmarketing reports and says it is not recommended for patients with severe gastroparesis. The manufacturers deny the allegations.
Where the litigation stands
MDL 3094 is being shaped by "cross-cutting" questions decided before individual cases. In an August 15, 2025 opinion, Judge Marston excluded parts of a plaintiffs' expert's gastroparesis opinions, rejecting reasoning that inferred delayed stomach emptying from symptoms or retained food alone. A further Rule 702 hearing on Cross-Cutting Issues 2 and 3 was scheduled for September 14–18, 2026. Vision-loss claims were placed in their own MDL 3163 in December 2025 so the judge can set how closely the two dockets are coordinated.
Who may qualify
People who took a GLP-1 drug and were diagnosed with gastroparesis, ileus, intestinal obstruction or NAION may qualify. Given the court's focus on objective testing, records such as a gastric emptying study, imaging or an ophthalmology diagnosis, together with pharmacy records showing which drug and dose were used, are generally important.
Deadlines and next steps
Statutes of limitations vary by state and often run from the injury or from when its likely cause was discovered. Read the full Ozempic lawsuit guide for an evidence checklist, and see our settlement amounts hub for how TortAdvisor reports figures only once they are documented.
Frequently asked questions
Is there an Ozempic settlement?
No global settlement or payout program had been announced in MDL 3094 or MDL 3163 as of November 2026. The court is still resolving cross-cutting expert questions that apply to many cases at once. Because nothing has been resolved, any per-case dollar figure you see online is a projection, not an amount set by a court or agreement.
Do I need a gastric emptying study?
Objective testing appears to matter. In its August 15, 2025 opinion the court pointed to the medical consensus that objective testing is needed to diagnose gastroparesis and excluded expert reasoning that inferred delayed emptying from symptoms or retained food alone. How a diagnosis was made, and when, may therefore be central to a claim, so keep copies of any testing records.
Are vision-loss (NAION) claims part of the Ozempic MDL?
No. On December 15, 2025 the JPML created a separate MDL 3163 for non-arteritic anterior ischemic optic neuropathy claims, assigned to the same judge so she can coordinate the two dockets. It listed 278 pending actions on November 2, 2026. In Europe, regulators concluded in June 2025 that NAION is a very rare side effect of semaglutide.
Which drugs are involved?
The 2024 transfer order names Novo Nordisk's semaglutide products Ozempic, Wegovy and Rybelsus, and Eli Lilly's Trulicity (dulaglutide) and Mounjaro (tirzepatide). Whether a particular drug or diagnosis supports a claim depends on medical records and state law; pharmacy records should document the brand and dates of use.
Sources
- Judicial Panel on Multidistrict Litigation – Pending MDL Dockets by Actions Pending (Nov. 2, 2026)
- JPML – Transfer Order, MDL 3094 (Feb. 2, 2024)
- U.S. District Court, E.D. Pa. – MDL 3094, GLP-1 RAs Products Liability Litigation (GI Injuries)
- JPML – Transfer Order, MDL 3163 (Dec. 15, 2025)
- U.S. FDA – Ozempic prescribing information (revised Oct. 2025)
- European Medicines Agency – PRAC concludes NAION is a very rare side effect of semaglutide medicines
Ozempic questions answered, with sources
State filing deadlines keep running
There is no Ozempic settlement, and 4,082 stomach-injury cases are already pending in MDL 3094. Your state’s deadline usually runs from when you learned of the injury, not from any settlement. MDL 3094 court page
Free · Confidential · No obligation
Free Ozempic Case Review
Tell us what happened and a trained case advisor will review it. You choose whether you want to be contacted.
- 1Share the basicsYour GLP-1 drug, diagnosis, tests and dates.
- 2A case advisor reviews itAgainst the court’s gastric emptying study rule and your state deadline.
- 3You decide what happens nextNo cost and no obligation.
- Sourced to the courtJPML reports and E.D. Pa. orders
- Every answer is citedEach answer links its primary source
- Free and confidentialNo cost and no obligation to continue
- Not a law firmA trained case advisor makes the first contact
Prefer to talk it through?
TortAdvisor is not a law firm and does not give legal advice. A trained case advisor, not an attorney, may make the first contact. See our partner list and privacy policy.
Filter Posts
Browse by Category
